Actinium Pharmaceuticals Company Leadership
| ATNM Stock | USD 6.67 0.58 8.00% |
Actinium Pharmaceuticals employs about 49 people. The company is managed by 36 executives with a total tenure of roughly 179 years, averaging almost 4.0 years of service per executive, having 1.36 employees per reported executive. Analysis of Actinium Pharmaceuticals' management performance can provide insight into the firm performance.
| Kaushik Dave CEO President CEO, Director |
| Sandesh Seth Chairman Chairman of the Board |
Actinium |
Actinium Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Actinium Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Actinium will maintain a workforce of about 50 employees by May 2024.Actinium Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.3317) % which means that it has lost $0.3317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9492) %, meaning that it created substantial loss on money invested by shareholders. Actinium Pharmaceuticals' management efficiency ratios could be used to measure how well Actinium Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to grow to -0.57. In addition to that, Return On Capital Employed is likely to grow to -0.68. At this time, Actinium Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 19th of April 2024, Total Current Assets is likely to grow to about 82.2 M, though Non Currrent Assets Other are likely to grow to (0.95).As of the 19th of April 2024, Common Stock Shares Outstanding is likely to grow to about 27.9 M, while Net Loss is likely to drop (31.2 M).
Actinium Pharmaceuticals Workforce Comparison
Actinium Pharmaceuticals is rated below average in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 4,828. Actinium Pharmaceuticals claims roughly 49.0 in number of employees contributing just under 2% to equities under Health Care industry.
Actinium Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Actinium Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Actinium Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Actinium Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2018-06-01 | 2.0 | 2 | 1 | 17,000 | 75,000 |
| 2018-03-01 | 5.3333 | 16 | 3 | 209,730 | 675,000 |
| 2017-06-01 | 4.0 | 4 | 1 | 16,000 | 250,000 |
| 2017-03-01 | 2.25 | 9 | 4 | 1,521,577 | 557,212 |
| 2016-06-01 | 0.2361 | 17 | 72 | 1,210,500 | 615,551 |
| 2015-06-01 | 0.5 | 4 | 8 | 5,850,452 | 159,024 |
| 2013-12-01 | 2.0 | 2 | 1 | 724,950 | 0.00 |
| 2013-09-01 | 2.0 | 4 | 2 | 761,068 | 0.00 |
Actinium Pharmaceuticals Notable Stakeholders
An Actinium Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Actinium Pharmaceuticals often face trade-offs trying to please all of them. Actinium Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Actinium Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Kaushik Dave | President CEO, Director | Profile | |
| MS MBA | Chairman CEO | Profile | |
| Sandesh Seth | Chairman of the Board | Profile | |
| Nitya Ray | Executive Vice President Head - Product Development, Manufacturing and Supply Chain | Profile | |
| Cynthia Pussinen | Executive Vice President - Technical Operations and Supply Chain | Profile | |
| Jehan Rowlands | Vice President and Head - Regulatory Affairs | Profile | |
| Robert Daly | Vice President Head - Clinical Operations | Profile | |
| Steven Price | Vice President - Clinical and Commercial Strategy | Profile | |
| Vijay Reddy | Vice President Clinical Development | Profile | |
| Mamata Gokhale | Vice President Global Head of Regulatory Affairs | Profile | |
| Qing Ling | Vice President Head of Radiation Sciences | Profile | |
| Steven BS | CFO Secretary | Profile | |
| Dragan Cicic | COO, Chief Medical Officer | Profile | |
| Sergio Traversa | Interim CFO, Independent Director | Profile | |
| David Nicholson | Independent Director | Profile | |
| CDavid Nicholson | Lead Independent Director | Profile | |
| Ajit Shetty | Independent Director | Profile | |
| Richard Steinhart | Director | Profile | |
| C Nicholson | Independent Director | Profile | |
| Jeffrey Chell | Independent Director | Profile | |
| Sunitha Lakshminarayanan | Head VP | Profile | |
| Elaina Haeuber | VP Operations | Profile | |
| Qing Liang | VP Sciences | Profile | |
| Dale Ludwig | Chief Scientific Officer | Profile | |
| Jenny Hsieh | Chief Officer | Profile | |
| Anil Kapur | Chief Commercial Officer | Profile | |
| Niva Almaula | Chief Business Officer | Profile | |
| MBA MS | Chairman CEO | Profile | |
| Bernie PMP | Executive Management | Profile | |
| Paul Esq | Vice Counsel | Profile | |
| Dr MS | VP Operations | Profile | |
| Steve OLoughlin | Principal Financial and Accounting Officer | Profile | |
| Arun Swaminathan | Chief Officer | Profile | |
| Mark Berger | Chief Medical Officer | Profile | |
| David Gould | Senior Affairs | Profile | |
| Avinash MD | Chief Officer | Profile |
About Actinium Pharmaceuticals Management Performance
The success or failure of an entity such as Actinium Pharmaceuticals often depends on how effective the management is. Actinium Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Actinium management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Actinium management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.57) | |
| Return On Capital Employed | (0.71) | (0.68) | |
| Return On Assets | (0.60) | (0.57) | |
| Return On Equity | (1.34) | (1.27) |
The data published in Actinium Pharmaceuticals' official financial statements usually reflect Actinium Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Actinium Pharmaceuticals. For example, before you start analyzing numbers published by Actinium accountants, it's critical to develop an understanding of what Actinium Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Actinium Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Actinium Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Actinium Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Actinium Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Actinium Pharmaceuticals' management manipulating its earnings.
Actinium Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Actinium Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Actinium Pharmaceuticals within its industry.Actinium Pharmaceuticals Manpower Efficiency
Return on Actinium Pharmaceuticals Manpower
| Revenue Per Employee | 1.7K | |
| Revenue Per Executive | 2.2K | |
| Net Loss Per Employee | 996.3K | |
| Net Loss Per Executive | 1.4M | |
| Working Capital Per Employee | 1.4M | |
| Working Capital Per Executive | 1.9M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Actinium Stock analysis
When running Actinium Pharmaceuticals' price analysis, check to measure Actinium Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actinium Pharmaceuticals is operating at the current time. Most of Actinium Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Actinium Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actinium Pharmaceuticals' price. Additionally, you may evaluate how the addition of Actinium Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Actinium Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.33) | Return On Equity (0.95) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.